Orchestra BioMed Holdings, Inc. (OBIO) Return on equity 2022–2025
Orchestra BioMed Holdings, Inc. (OBIO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-98.4%FY2025 · since FY2022: -64.0% → -98.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -98.4% | +86.8 pp |
| FY2024 | -185.2% | -113.0 pp |
| FY2023 | -72.2% | -8.2 pp |
| FY2022 | -64.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More OBIO financial trends
OBIO RevenueOBIO Net incomeOBIO Net marginOBIO Gross profitOBIO Gross marginOBIO Operating incomeOBIO Operating marginOBIO Operating cash flowOBIO Free cash flowOBIO Capital expendituresOBIO Stock buybacksOBIO Dividends paidOBIO Total assetsOBIO Total liabilitiesOBIO Shareholders’ equityOBIO overview →